
UPDATE TO THE SHAREHOLDERS ON THE ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN

The Board of Directors (“**Board**”) of OUE Lippo Healthcare Limited (the “**Company**”) refers to the Company’s announcements on 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019 and 31 May 2019 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun (“**David Lin**”).

As announced on 17 January 2019, the Company obtained a Final Arbitration Award (“**Award**”) against David Lin in the arbitration proceedings before the Singapore International Arbitration Centre. The Company subsequently obtained permission from the Hong Kong High Court to enforce the Award as a Hong Kong judgment (the “**Enforcement Order**”), and an interim Mareva Injunction to restrain David Lin from dealing with his assets in Hong Kong up to the aggregate value of RMB 58,837,898.20, USD 32,840,185.87, and SGD 842,822.66 (the “**Mareva Injunction Order**”).

As announced on 29 January 2019 and 28 February 2019, David Lin subsequently applied to discharge and/or vary the Mareva Injunction Order and to set aside the Enforcement Order in Hong Kong.

The Board wishes to update the shareholders that David Lin’s applications were heard before the Hong Kong High Court on 25 June 2019, during which the Hong Kong High Court dismissed both of David Lin’s applications, and ordered David Lin to pay costs on an indemnity basis for the costs incurred by the Company in defending the applications.

The Company is presently working with its counsel to enforce the Award and recover payments from David Lin pursuant to the Award in Hong Kong. The Company will make further announcements as and when there are any material developments in the enforcement proceedings against David Lin.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
26 June 2019

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**") in accordance with Rules 226(2) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com